Advaxis to Present at the French Biotech Tour

UCSF-Mission Bay Conference Center

San Francisco, CA | Wednesday, March 17, 2010

NORTH BRUNSWICK, N.J.--(EON: Enhanced Online News)--Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes immunotherapy company, has been invited to present at the French Biotech Tour Conference, Wednesday, March 17 at the UCSF-Mission Bay Conference in San Francisco. Some notable international healthcare companies slated to attend include:

• Merck Research Laboratories (NYSE: MRK)
• Novartis Vaccines and Diagnostics (NYSE: NVS)
• Sanofi Pasteur (NYSE: SNY)

For more information on attending the conference, please visit the Ubifrance website: http://www.ubifrance-events.com.

About the French Biotech Tour

The French Biotech Tour California (FBT) is a US/French partnering event with a focus on infectious diseases and vaccines. The event will consist of the US and French company presentations, pre-booked, validated one-to-one meetings and informal networking opportunities. The FBT is organized by Ubifrance, the French agency for international business development, in partnership with Lyonbiopole, Office for Science and Technology of the French Consulate in Los Angeles and French BioBeach in San Diego, CA.

About Advaxis, Inc.

Advaxis is a biotechnology company developing proprietary, live, attenuated Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development, directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research – UK. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board.

For further information, please visit the Company’s portals on the following sites:

advaxis.com | facebook | twitter | LinkedIn

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.